Morepen Laboratories Limited AI Stock Analysis
Want to see IN:MOREPENLAB full AI Analyst Report?
Morepen Laboratories Limited (MOREPENLAB) AI Stock Analysis
Morepen Laboratories Limited
(NSE:MOREPENLAB)
The overall score of 57 reflects a company with a strong balance sheet and bullish technical momentum, but these are offset by significant fundamental weaknesses. The most impactful factor is the poor cash flow generation, with declining operating cash and deeply negative free cash flow, which raises sustainability concerns. Additionally, the high P/E ratio of 44.82 makes the stock look overvalued given its recent earnings decline. Positive price trends and a conservative capital structure provide some support, but the financial and valuation risks dominate the assessment.
Morepen Laboratories Limited (MOREPENLAB) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 50.19B
- Dividend Yield
- 0.22%
- Average Volume (3M)
- 917.64K
- Price to Earnings (P/E)
- 26.5
- Beta (1Y)
- 0.81
- Revenue Growth
- 30.20%
- EPS Growth
- 91.17%
- Country
- India
- Employees
- 2,152
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Morepen Laboratories Limited Business Overview & Revenue Model
Company Description
Morepen Laboratories Limited is an Indian pharmaceutical company primarily engaged in the development, manufacturing, marketing, and distribution of active pharmaceutical ingredients (APIs), proprietary and generic pharmaceutical formulations, and a...
Morepen Laboratories Limited Financial Statement Overview
Summary
Financial performance is mixed. The Income Statement (Score: 58) shows steady revenue growth and improving gross margins, but declining operating and net margins with a 20% drop in net income. The Balance Sheet (Score: 72) is strong with low leverage and a solid equity base, though ROE has fallen significantly. The Cash Flow Statement (Score: 35) is a major concern, with declining operating cash flow and deeply negative free cash flow due to heavy capex, raising liquidity risks. The overall financial picture is weighed down by poor cash generation.
Income Statement
58NeutralBalance Sheet
72PositiveCash Flow
35Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.86B | 18.06B | 18.30B | 17.02B | 14.18B | 15.42B |
| Gross Profit | 8.97B | 6.82B | 6.30B | 6.18B | 2.19B | 4.81B |
| EBITDA | 2.97B | 1.73B | 1.92B | 1.73B | 856.66M | 1.57B |
| Net Income | 1.89B | 948.77M | 1.18B | 961.60M | 386.75M | 1.02B |
Balance Sheet | ||||||
| Total Assets | 23.06B | 19.36B | 17.78B | 12.93B | 11.10B | 10.70B |
| Cash, Cash Equivalents and Short-Term Investments | 2.71B | 916.99M | 1.27B | 169.45M | 216.66M | 158.03M |
| Total Debt | 3.23B | 2.08B | 1.05B | 289.99M | 251.64M | 1.33B |
| Total Liabilities | 9.24B | 6.89B | 5.91B | 4.46B | 3.58B | 4.92B |
| Stockholders Equity | 13.81B | 12.46B | 11.56B | 8.47B | 7.53B | 5.79B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.44B | -919.76M | -79.61M | -1.37B | -1.25B |
| Operating Cash Flow | 0 | 162.28M | 320.57M | 733.75M | -911.71M | -577.58M |
| Investing Cash Flow | 0 | -1.22B | -3.22B | -833.00M | -465.09M | -316.79M |
| Financing Cash Flow | 0 | 1.13B | 3.00B | 52.05M | 1.44B | 663.34M |
Morepen Laboratories Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MOREPENLAB, the sentiment is Negative. The current price of 90.65 is below the 20-day moving average (MA) of 105.89, below the 50-day MA of 116.37, and above the 200-day MA of 68.65, indicating a neutral trend. The MACD of -7.60 indicates Positive momentum. The RSI at 35.58 is Neutral, neither overbought nor oversold. The STOCH value of 14.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MOREPENLAB.
Morepen Laboratories Limited Peers Comparison
Overall Rating
IN:ALEMBICLTD69Neutral
IN:WINDLAS66Neutral
IN:HIKAL57Neutral
IN:MOREPENLAB57Neutral
IN:SOLARA50Neutral
IN:INDOCO43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | INR 28.62B | 8.07 | ― | 2.16% | -4.66% | 9.58% | |
| 66Neutral | INR 20.24B | 30.70 | ― | 0.64% | 18.48% | -0.41% | |
| 57Neutral | INR 27.35B | -555.15 | ― | 0.27% | 8.93% | -149.51% | |
| 57Neutral | INR 49.67B | 26.46 | ― | 0.22% | 30.20% | 91.17% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | INR 30.74B | 82.98 | ― | ― | 27.30% | 456.80% | |
| 43Neutral | INR 21.54B | 68.55 | ― | 0.09% | 10.75% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:MOREPENLAB | Morepen Laboratories Limited | 90.65 | 47.59 | 110.53% | |
| IN:ALEMBICLTD | Alembic Limited | 111.44 | 16.07 | 16.86% | |
| IN:HIKAL | Hikal Limited | 221.85 | 4.22 | 1.94% | |
| IN:INDOCO | Indoco Remedies Limited | 233.35 | -19.63 | -7.76% | |
| IN:SOLARA | Solara Active Pharma Sciences Ltd. | 639.30 | 116.95 | 22.39% | |
| IN:WINDLAS | Windlas Biotech Ltd. | 980.80 | 213.40 | 27.81% |
Morepen Laboratories Limited Corporate Events
Morepen Launches First U.S. Prescription Generic, Expanding Beyond APIs
Morepen Laboratories has launched Desloratadine Tablets USP, 5 mg, as its first U.S. prescription generic through wholly owned subsidiary Morepen Bio Inc. Available in 100-count and 500-count packs, the product builds on the company’s established sup...
Morepen Files First U.S. ANDA to Bolster Integrated CDMO Platform
Morepen Laboratories has filed its first Abbreviated New Drug Application with the U.S. Food and Drug Administration for Sitagliptin Tablets USP in three strengths, marking its entry into U.S.-bound finished dosage submissions. The move extends its C...
Morepen Laboratories posts e‑voting results for 41st AGM
Morepen Laboratories Limited has reported the e‑voting results for its 41st Annual General Meeting held on September 26, 2026 via video conferencing and other audio‑visual means. The company provided remote and AGM e‑voting facilities in line with Co...
Morepen Laboratories Publishes AGM and Dividend Notice for Investors
Morepen Laboratories Limited has informed the stock exchanges that it published newspaper notices regarding its 41st Annual General Meeting, dividend declaration and the associated record date. The disclosures appeared in the Financial Express and Ja...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 17, 2026
